OTCM
YSBIF
, Last price
USD
Name
YSB Inc
Chart & performance
P/E
—
P/S
—
EPS
0.24
Vol. 1Y
—
Shs. 5Y
40.86%
Rev. 5Y
28.16%
Div Yld LY
—
Div Yld TTM
—
Revenues
20.97b
+17.13%
Net income
153m
+409.66%
CFO
638m
-2.77%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
YSB Inc. provides a comprehensive digital platform tailored for the Chinese pharmaceutical sector, supporting a wide array of stakeholders such as drug companies, distributors, vendors, pharmacies, and primary healthcare facilities. Its key offerings feature ClouDiagnos, a specialized diagnostic testing service; wePharmacy, an intelligent, unmanned pharmaceutical booth accessible 24/7 that facilitates connections between customers and professional pharmacist services; a suite of Software-as-a-Service (SaaS) solutions; and YSB eLearn, which delivers online courses to prepare individuals for pharmacist qualification examinations. Beyond its digital offerings, the company engages in the wholesale and retail distribution of pharmaceutical and healthcare merchandise, and additionally provides medical testing services. The company was established in 2015 and is headquartered in Guangzhou, China.
Legal address
西湾路802号芙蓉路大公馆310119号
大开曼岛 KY1-1205
KY
大开曼岛 KY1-1205
KY
Headquarters
海珠区新港中路397号品牌街8号
广州市, GD 510000
CN
广州市, GD 510000
CN
Address
Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman
Grand Cayman KY1-1205
KY
Grand Cayman KY1-1205
KY
Address
No.8 brand street, No. 397, Xingang Middle Road, Haizhu District
Guangzhou, GD 510000
CN
Guangzhou, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||